Fatty acid vesicles acting as expanding horizon for transdermal delivery
Source abstract
Abstract
The body is protected against the external environment by the skin due to its physical barrier nature. Stratum corneum composed of corneocytes surrounded by lipid region performs a major barrier function as it lies in the uppermost area of skin. Alteration in barrier function, increase in permeability, and disorganization of stratum corneum represent diseased skin. Drugs applied to the diseased skin should induce a local effect at the site of application or area close to it along with cutaneous absorption rather than percutaneous absorption. Conventional formulations like ointments, gels, and creams suffer from the drawback of limited local activity. For the enhancement of drug penetration and localization of the drug at the site of action approaches explored are liposomes, niosomes, ethosomes microparticles, and solid lipid nanoparticles. Vesicles composed of fatty acids like oleic acid and linoleic acid represent the new approach used for transdermal penetration and localization. In this review article, our major aim was to explore the applications of fatty acid vesicles for transdermal delivery of various bioactives.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Lipid Membrane Structure and Behavior · Bee Products Chemical Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, Shivalik College of Pharmacy, Nangal, Punjab, India;
I. K. Gujral Punjab Technical University, Jallandhar, Punjab, India;
Department of Pharmaceutics, Rayat Bahra College of Pharmacy, Hoshiarpur, Punjab, India;
Department of Pharmaceutical Chemistry, Shivalik College of Pharmacy, Nangal, Punjab, India;
Department of Pharmaceutics, Guru Nanak Institute of Pharmacy, Hoshiarpur, Punjab, India
References (52)
Show source-provided references
1. Agarwal R · Pharm Tech · 2002 · 48
2. 10.1016/j.colsurfa.2013.10.04510.1016/j.colsurfa.2013.10.045 ↗
3. 10.1016/S0005-2736(01)00400-X10.1016/S0005-2736(01)00400-X ↗
4. 10.1023/A:101592170225810.1023/A:1015921702258 ↗
5. 10.1016/j.colsurfb.2007.01.01410.1016/j.colsurfb.2007.01.014 ↗
6. 10.1016/j.ddtec.2005.05.00310.1016/j.ddtec.2005.05.003 ↗
7. 10.1016/j.bbamem.2006.06.02110.1016/j.bbamem.2006.06.021 ↗
8. 10.1111/dsu.1230010.1111/dsu.12300 ↗
9. 10.1021/bi00406a01310.1021/bi00406a013 ↗
10. 10.1016/S0889-857X(05)70358-610.1016/S0889-857X(05)70358-6 ↗
11. 10.1023/A:100674680710410.1023/A:1006746807104 ↗
12. Dhillon V · Am J Pharm Tech Res · 2011 · 1 · 1
13. 10.1021/la00007a02010.1021/la00007a020 ↗
14. Ehdaie B. · J Pharm Biomed Sci · 2011 · 1 · 161
15. 10.1211/002235701177645010.1211/0022357011776450 ↗
16. 10.1038/jid.1983.1210.1038/jid.1983.12 ↗
17. 10.1016/j.ijpharm.2006.12.00510.1016/j.ijpharm.2006.12.005 ↗
18. 10.1038/243232a010.1038/243232a0 ↗
19. Grassi W · Eur J Radiol · 1998 · 27 · S1810.1016/S0720-048X(98)00038-2 ↗
20. 10.1126/science.108990410.1126/science.1089904 ↗
21. 10.1021/bi00611a01410.1021/bi00611a014 ↗
22. 10.1093/rheumatology/41.3.27910.1093/rheumatology/41.3.279 ↗
23. 10.1016/j.ejpb.2008.11.00110.1016/j.ejpb.2008.11.001 ↗
24. Kong JF · Am J Physiol Heart Circ Physiol · 2002 · 282 · H71710.1152/ajpheart.00257.2001 ↗
25. 10.3109/21691401.2013.76944610.3109/21691401.2013.769446 ↗
26. 10.1007/s11095-006-0143-710.1007/s11095-006-0143-7 ↗
27. 10.1016/j.ijpharm.2005.02.02110.1016/j.ijpharm.2005.02.021 ↗
28. 10.1001/archdermatol.2009.29110.1001/archdermatol.2009.291 ↗
29. 10.1021/jp027719910.1021/jp0277199 ↗
30. 10.1021/jp981234w10.1021/jp981234w ↗
31. 10.1016/S0168-3659(98)00087-X10.1016/S0168-3659(98)00087-X ↗
32. Mittal R · J Pharm · 2013
33. 10.1208/s12249-010-9420-110.1208/s12249-010-9420-1 ↗
34. 10.1529/biophysj.106.09616410.1529/biophysj.106.096164 ↗
35. 10.1021/bi991954910.1021/bi9919549 ↗
36. 10.1111/j.1600-0625.2008.00786.x10.1111/j.1600-0625.2008.00786.x ↗
37. 10.1016/j.bpj.2011.12.02610.1016/j.bpj.2011.12.026 ↗
38. 10.1002/cphc.20060012510.1002/cphc.200600125 ↗
39. 10.1001/archinte.163.13.151410.1001/archinte.163.13.1514 ↗
40. 10.1016/j.colsurfb.2006.01.00110.1016/j.colsurfb.2006.01.001 ↗
41. 10.1097/00002281-199905000-0000210.1097/00002281-199905000-00002 ↗
42. Sekulic A · Curr Opin Oncol · 2013 · 25 · 21810.1097/CCO.0b013e32835ff438 ↗
43. Sharma A · ISRN Pharm · 2012
44. Sharma A · World J Pharm Pharm Sci · 2013 · 2 · 6448
45. 10.1517/1742524090307102910.1517/17425240903071029 ↗
46. 10.1002/14651858.CD002946.pub210.1002/14651858.CD002946.pub2 ↗
47. 10.3109/21691401.2013.79435110.3109/21691401.2013.794351 ↗
48. 10.1016/j.cocis.2007.05.00510.1016/j.cocis.2007.05.005 ↗
49. Wu TP · J Drugs Dermatol · 2013 · 12 · 568
50. 10.3109/1071754100368098110.3109/10717541003680981 ↗
51. Zakir F, Vaidya B, Malik B, Vyas SP. 2011. Fatty acid vesicles: promising drift in colloidal drug carriers. In: Vyas SP, Murthy RSR, Narang RK, Eds. Nanocolloidal Carriers: Site Specific and Controlled Drug Delivery. New Delhi: CBS publishers. pp. 201–218.
52. 10.1021/bi961685b10.1021/bi961685b ↗